TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* physician-diagnosed asthma~* age 6 or older~* pre-bronchodilator forced expiratory volume (FEV1) of at least 60% of predicted~* beta-agonist reversibility OR airways hyperreactivity by methacholine challenge~* Juniper Asthma Control Score of 1.5 or greater if not on daily controller~* good current health~Exclusion Criteria:~* current or past smoking (greater than 20 pack-years)~* chronic or current oral steroid therapy~* pregnancy, lack of effective contraception (when appropriate), lactation

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone (Type: ACTIVE_COMPARATOR): Participants continued fluticasone (100 microgram twice daily) treatment.
- Montelukast (Type: EXPERIMENTAL): Participants were changed to Montelukast (5 or 10 mg each night).
- Fluticasone plus salmeterol (Type: EXPERIMENTAL): Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy man or woman~* Body mass index between 18 and 29.9 kg/m2, inclusive~Exclusion Criteria:~* Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the gastrointestinal (GI) tract~* Any surgery on the small intestine or colon, excluding appendectomy~* Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematologic, metabolic, endocrine, neurologic, psychiatric disease, or any condition that may interfere with the subject successfully completing the trial or that would present a safety risk to the subject.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- AZD1722 (Type: EXPERIMENTAL): Dose escalation from 5 mg to 90 mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: rTMS in the Treatment of PTSD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* primary diagnosis of PTSD as determined by a structured interview using the Mini International Neuropsychiatric Interview (MINI)~* no change in psychotropic medications within 4 weeks before the start of rTMS~* age \> 19 years and \< 70 years~* competency to give informed consent~Exclusion Criteria:~* any non-fixed metal object or implant (including cochlear implants) in brain, skull, scalp, or neck within 30 cm of the magnetic rTMS coil~* implantable devices, including cardiac pacemakers and defibrillators~* other contraindications to rTMS, including history of seizures (except childhood febrile seizures) or recent and unexplained syncope, first-degree relative with a history of epilepsy, treatment with a medication known to substantially decrease the seizure threshold, or pregnancy~* psychiatric diagnoses of psychosis or psychotic disorder (including psychotic depression), bipolar type I disorder, or organic mental disorders~* substance abuse/dependence within the past 3 months~* active suicidal risk as judged by the clinician~* borderline or antisocial personality disorder~* acute medical illness, including cancer~* any significant central nervous system disorder, such as brain mass, stroke, etc.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Low-frequency (1 Hz) rTMS (Type: ACTIVE_COMPARATOR): Low-frequency active stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
- High-frequency (10 Hz) rTMS (Type: ACTIVE_COMPARATOR): High-frequency active stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
- Sham rTMS (Type: PLACEBO_COMPARATOR): Sham stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S-1 and Radiotherapy in Elderly Patients With Esophageal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented diagnosis of esophageal Cancer~* Disease must be encompassed in a radiotherapy field.Patients with celiac, perigastric, mediastinal or supraclavicular adenopathy are eligible~* age:70-85 years~* Written informed consent.~* Performance status of 0 to 2~* Neutrophil count \>1.5 x 10 to the 9th power/L and platelets \> 100 x 10 to the 9th power/L.~* Hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (ULN) Alanine transaminase (ALT) and aspartate transaminase (AST) less than or equal to 2.5 times ULN (or less than or equal to 5 times ULN in case of known liver involvement~* Renal: Serum Creatinine less than or equal to 1.5 times upper limit of normal (ULN)~Exclusion Criteria:~* Evidence of tracheoesophageal fistula, or invasion into the trachea or major bronchi.~* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years (For example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible).~* Prior systemic chemotherapy or radiation therapy for esophageal cancer

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Chemoradiotherapy with S-1 (Type: EXPERIMENTAL): radiation 54Gy over 30 fractions,and concurrent with s-1 on days 1-14 and 29-42

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a confirmed S. mansoni infection (positive POC-CCA test result and at least one positive out of triplicate Kato-Katz thick smears)~* Subject is aged between 5 and 18 years and otherwise in good health~* Subject has received no recent praziquantel treatment in the past month~* Subject has provided oral assent and provided written informed consent signed by parents/legal guardian~* Subject is able and willing to provide multiple stool and urine samples during study~Exclusion Criteria:~* Known allergy to study medication (i.e. praziquantel and albendazole)~* Pregnancy~* Lactating

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Control group (A) (Type: ACTIVE_COMPARATOR): 1x praziquantel: Children assigned to group A receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive no further treatment until the final visit (week 8).
- Intervention group (B) (Type: EXPERIMENTAL): 4x praziquantel: Children assigned to group B receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive three consecutive praziquantel treatments (40 mg/kg) in the following six weeks with 2 weeks intervals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ivermectin in the Treatment of Head Lice

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Head lice infestation confirmed by detection combing by study staff~* previous (within 6 weeks) use of a topical insecticide product~* minimum 15kg weight~* providing informed consent~Exclusion Criteria:~* pregnant or nursing patients~* households with 7 or more infested patients~* households where there are other known infested household members not participating~* head lice treatment within 2 weeks of entry~* active scalp infection~* any difficulty with combing assessment~* patient from region endemic for certain parasitic worm diseases

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ivermectin (Type: EXPERIMENTAL): ivermectin Stromectol®)
- Malathion (Type: ACTIVE_COMPARATOR): malathion(Prioderm®)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Riluzole in Hereditary Cerebellar Ataxia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with genetically confirmed diagnosis of hereditary cerebellar ataxia~Exclusion Criteria:~* Concomitant experimental therapy for ataxia~* Serious systemic illnesses~* Pregnancy

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Riluzole (Type: EXPERIMENTAL): Riluzole 50 mg is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)
- Placebo comparator (Type: PLACEBO_COMPARATOR): Placebo is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must have completed the 12-week study D3820C00004 through Visit 8.~* Provision of written informed consent prior to any study-specific procedures.~* Men and women who were between the ages of \>18 and \<85 years at the time of the screening visit for study D3820C00004.~* Continuing to receive a stable maintenance opioid regimen consisting of a total daily dose of 30 mg to 1000 mg of oral morphine, or equianalgesic amount(s) of 1 or more other opioid therapies.~* Willingness to continue abstinence from all laxatives and other bowel regimens including prune juice and herbal products throughout this additional 12-week treatment period, and to use only bisacodyl as rescue medication if a bowel movement (BM) has not occurred within at least 72 hours of the last recorded BM.~Exclusion Criteria:~* Patients receiving opioid regimen for treatment of pain related to cancer.~* History of cancer within 5 years from the screening visit of study D3820C00004 with the exception of basal cell cancer and squamous cell skin cancer.~* Medical conditions and treatments associated with diarrhea, intermittent loose stools, or constipation.~* Other issues related to the gastrointestinal tract that could impose risk to the patient.~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- NKTR-118 12.5mg (Type: EXPERIMENTAL): None
- NKTR-118 25mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zenith(R) Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Clinical Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Abdominal aortic and aortoiliac aneurysms with diameter greater than or equal to 5 cm~Exclusion Criteria:~* Proximal neck less than 4 mm or greater than or equal to 15 mm in length unless otherwise compromised to preclude seal~* Renal artery stenosis greater than 50 percent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Zenith(R) Fenestrated AAA Endovascular Graft

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* - Male or female Outpatients 18 years and older.~* Patients with hypertension defined as the following:~* Newly diagnosed hypertensive patients should have a MSDBP \> 95 mmHg and \< 110 mmHg.at Visit 1 and 2, Pre-treated hypertensive patients should have a MSDBP \> 95 mmHg and \< 110 mmHg at Visit 2~* For entrance into the double-blind treatment period (Visit 3), all patients should have a MSDBP of \> 90 mmHg and \< 110 mmHg~* Patients must have given written informed consent to participate and be willing to participate in the entire study~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of a Decision Aid Intervention for Family-building After Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Completed cancer treatment known to have gonadotoxic effects (e.g., systemic chemotherapy, surgery affecting reproductive organs or hormone regulation, and/or pelvic radiation)~* Understands verbal and written English~* Desires future children or uncertainty regarding family-building plans~* Access to the Internet and use of a computer, tablet, or smartphone~Exclusion Criteria:~* Currently undergoing cancer treatment excluding long-term adjuvant or maintenance therapies, such as tamoxifen~* Significant physical or mental disability that prevents completion of study activities~Note: Survivors on adjuvant maintenance or endocrine treatment, such as tamoxifen, will not be excluded because clinical guidelines allow treatment delay or hiatus to accommodate fertility preservation, egg extraction for surrogacy, or pregnancy for some patients, and because patients may be interested in alternative family-building options such as surrogacy or adopting.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Online Decision Aid (Type: EXPERIMENTAL): web-based psychosocial assessment questionnaires will be administered at baseline (T1; pre-intervention) and at one-month (T2) and three-month (T3) follow-up time points.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male subject~2. Subject voluntarily agrees to participate in this study~Exclusion Criteria:~1. Female.~2. Subject has a medical condition of disease including one or more.~3. Smoker

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- CT-P6 (Type: ACTIVE_COMPARATOR): Trastuzumab
- US-licensed Herceptin (Type: ACTIVE_COMPARATOR): Trastuzumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have symptoms suggestive of ACS that lasted at least 10 minutes at rest occurring within 7 days of randomization~* Have a diagnosis of ST-elevation myocardial infarction or non-ST elevation myocardial infarction/unstable angina (ie, chest pain or discomfort) (ST elevation is an abnormal finding from an ECG test) with at least 1 protocol-defined high risk feature~Exclusion Criteria:~* Active bleeding or high risk of bleeding or intracranial hemorrhage (bleeding within the skull enclosing the brain)~* Need for continued anticoagulant therapy~* Significantly impaired renal (kidney) or hepatic (liver) function~* Severe concomitant diseases such as cardiogenic shock (heart damage that results in insufficient blood supply to other parts or organs of the body), refractory ventricular arrhythmias (irregular contractions of the heart unresponsive to treatment), or any severe condition that would limit life expectancy of the patient to less than 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Rivaroxaban 1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
- 002 (Type: EXPERIMENTAL): Rivaroxaban/Placebo 1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
- 003 (Type: PLACEBO_COMPARATOR): Placebo 1 placebo tablet twice daily for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Colesevelam HCl On Bile Acid Kinetics

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have given written informed consent~* BMI 25-35 kg/m\^2, inclusive~* Normal liver and thyroid function~* No history of liver, biliary, or intestinal disease~Diabetic Subjects~* Diagnosed Type 2 Diabetes Mellitus~* HbA1C = 6.7-10%~Normal Subjects~* 2 hr OGTT glucose \< 140 mg/dL~* fasting glucose \< 100 mg/dL~* TG \< 150 mg/dL~* HDL cholesterol \>= 40 mg/dL~Impaired Glucose Tolerance Subjects~* 2 hr OGTT glucose \>= 140 and \< 200 mg/dL~Exclusion Criteria:~* T1DM or history of diabetic ketoacidosis~* treatment with blood pressure lowering therapy that has not been stable for three months before screening~* colesevelam HCl, cholestyramine, or colestipol treatment for hyperlipidemia within the last three months~* treatment with thiazolidinedione (TZD) at any time~* treatment with insulin within past 6 months~* treatment with antibiotics within last 3 months~* extreme sportsmen~* treatment with medication affecting liver or intestinal function within the last 3 months~* allergic or toxic rxn to colesevelam HCl~* history of dysphagia, swallowing disorders, or intestinal motility disorder~* Serum Triglycerides \> 500 mg/dL at visit 1~* Serum LDL-C \< 60 mg/dL at visit 1~* any condition or therapy investigator believes not in subjects best interest~* use of any investigational drug within 30 days before screening~* chronic treatment with oral corticosteroids at any time or acute treatment within last three months~* hyperthyroidism or treatment with thyroid hormone/levothyroxine

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Normal Glucose Metabolism (Type: None): Overweight and obese individuals that have normal glucose metabolism and their response to Colesevelam HCl
- Impaired Glucose Tolerance (Type: None): Overweight and obese individuals that have impaired glucose tolerance and their response to Colesevelam HCl
- Frank type 2 diabetes (Type: None): Overweight and obese individuals that have frank type 2 diabetes and their response to Colesevelam HCl

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete